Consolidated Statement Of Cash Flows

OncoTherapy Science, Inc. - Filing #7329199

Concept 2023-04-01 to
2024-03-31
As at
2024-03-31
2023-04-01 to
2024-03-31
As at
2023-03-31
2022-04-01 to
2023-03-31
2022-04-01 to
2023-03-31
As at
2022-03-31
Consolidated statement of cash flows
Statement of cash flows
Cash flows from operating activities
Profit (loss) before income taxes
-1,285,713,000 JPY
-1,006,572,000 JPY
-1,116,193,000 JPY
-1,116,420,000 JPY
Impairment losses
154,564,000 JPY
21,553,000 JPY
Interest expenses
218,000 JPY
JPY
Decrease (increase) in trade receivables
87,484,000 JPY
276,641,000 JPY
Subtotal
-1,225,319,000 JPY
-775,843,000 JPY
Decrease (increase) in inventories
25,618,000 JPY
131,423,000 JPY
Income taxes paid
-2,561,000 JPY
-2,896,000 JPY
Net cash provided by (used in) operating activities
-1,227,990,000 JPY
-794,901,000 JPY
Other, net
-16,233,000 JPY
-29,993,000 JPY
Interest paid
-109,000 JPY
JPY
Cash flows from investing activities
Purchase of property, plant and equipment
-2,627,000 JPY
-5,393,000 JPY
Proceeds from sale of property, plant and equipment
JPY
476,000 JPY
Net cash provided by (used in) investing activities
-33,354,000 JPY
-20,319,000 JPY
Cash flows from financing activities
Proceeds from issuance of shares
682,552,000 JPY
JPY
Net cash provided by (used in) financing activities
671,365,000 JPY
95,950,000 JPY
Other, net
-2,000 JPY
JPY
Net increase (decrease) in cash and cash equivalents
-589,978,000 JPY
-719,271,000 JPY
Cash and cash equivalents
527,656,000 JPY
1,117,635,000 JPY
1,836,906,000 JPY

Talk to a Data Expert

Have a question? We'll get back to you promptly.